EpirubicinDeoxycytidineAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsPancreatic NeoplasmsAntibiotics, AntineoplasticDrug Administration ScheduleFluorouracilCisplatinPaclitaxelTaxoidsDeoxycytidine KinaseBreast NeoplasmsTreatment OutcomeCyclophosphamideInfusions, IntravenousVinblastineBiliary Tract NeoplasmsDisease-Free SurvivalAdenocarcinomaChemotherapy, AdjuvantDose-Response Relationship, DrugNeutropeniaMaximum Tolerated DoseLung NeoplasmsSurvival RateDrug Resistance, NeoplasmDoxorubicinRazoxaneNeoadjuvant TherapyAntineoplastic AgentsCarcinoma, Non-Small-Cell LungNeoplasm MetastasisAnthracyclinesCarboplatinNeoplasm StagingEquilibrative Nucleoside Transporter 1Cell Line, TumorCombined Modality TherapyLeukopeniaDrug SynergismGranulocyte Colony-Stimulating FactorNauseaHematologic DiseasesOrganoplatinum CompoundsCarcinoma, Pancreatic DuctalIfosfamideCarcinoma, Transitional CellAlopeciaDisease ProgressionUrinary Bladder NeoplasmsVomitingMethotrexateLead RadioisotopesRibonucleoside Diphosphate ReductaseXenograft Model Antitumor AssaysStomatitisNeoplasmsRadiation-Sensitizing AgentsUrologic NeoplasmsAntineoplastic Agents, PhytogenicSurvival AnalysisCA-19-9 AntigenKaplan-Meier EstimateProlyl HydroxylasesNeoplasm Recurrence, LocalMice, NudeApoptosisReceptor, erbB-2EtoposideAntibodies, Monoclonal, HumanizedTegafurGallbladder NeoplasmsThrombocytopeniaArea Under CurvePrognosisCarcinomaTime FactorsDrug Screening Assays, AntitumorGuanineFollow-Up StudiesStomach NeoplasmsRibonucleotide ReductasesInhibitory Concentration 50Drug InteractionsQuinazolinesSoft Tissue NeoplasmsGlutamatesInjections, IntravenousRemission InductionNaphthacenesSarcomaLymphatic MetastasisAdministration, IntravesicalCell ProliferationLiver Neoplasms